Renal effects and safety of tirzepatide in subjects with and without diabetes: A systematic review and meta-analysis DOI
A B Kamrul-Hasan, Shinjan Patra, Deep Dutta

et al.

World Journal of Diabetes, Journal Year: 2024, Volume and Issue: 16(2)

Published: Dec. 30, 2024

Type 2 diabetes (T2D), as well obesity, are risk factors for chronic kidney disease (CKD) and end-stage renal disease. The impacts of glucose-lowering weight-lowering drugs their potential benefits in preventing CKD often guide clinicians choosing them appropriately. Only limited data based on randomized controlled trials (RCTs) is currently available the effects safety profile tirzepatide. To explore tirzepatide vs controls. RCTs involving patients receiving any indication intervention arm placebo or active comparator control were searched through multiple electronic databases. co-primary outcomes percent change from baseline (CFB) urine albumin-to-creatinine ratio (UACR) absolute CFB estimated glomerular filtration rate (eGFR; mL/min/1.73 m2); secondary outcome was tirzepatide's profile. RevMan web used to conduct meta-analysis using random-effects models. Outcomes presented mean differences (MD) ratios with 95% confidence intervals. Fifteen (n = 14471) mostly low bias (RoB) included. Over 26-72 weeks, 10 mg [MD -26.95% (-40.13, -13.76), P < 0.0001] 15 -18.03% (-28.58, -7.47), 0.0008] superior reductions UACR. Tirzepatide, at all doses, outperformed insulin Compared placebo, UACR reduction greater subjects T2D than those obesity but without (MD -33.25% -7.93%; 0.001). eGFR doses comparable [5 mg: MD 0.36 (-1.41, 2.14); 1.17 (-0.22, 2.56); 1.42 (-0.04, 2.88)]; > 0.05 all] insulin. Tirzepatide (pooled separate doses) did not increase risks adverse events, urinary tract infection, nephrolithiasis, acute injury, cancer compared insulin, glucagon-like peptide-1 receptor agonists. Short-term RoB suggests that positively detrimental T2D, a reassuring Larger warranted prove longer-term tirzepatide, which might also prevent decline worsening CKD.

Language: Английский

Tirzepatide and Cancer Risk in Individuals with and without Diabetes: A Systematic Review and Meta-Analysis DOI Creative Commons
A B Kamrul-Hasan, Muhammad Shah Alam, Deep Dutta

et al.

Endocrinology and Metabolism, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 15, 2025

BackgroundData on the carcinogenic potential of tirzepatide from randomized controlled trials (RCTs) are limited. Furthermore, no meta-analysis has included all relevant RCTs to assess cancer risk associated with tirzepatide. MethodsRCTs involving patients receiving in intervention arm and either a placebo or any active comparator control were searched through electronic databases. The primary outcome was overall cancer, secondary outcomes risks specific types versus groups. ResultsThirteen 13,761 participants analyzed. Over 26 72 weeks, pooled groups had identical (risk ratio, 0.78; 95% confidence interval, 0.53 1.16; P=0.22). two comparable without diabetes. In subgroup analyses, also similar placebo, insulin, glucagon-like peptide-1 receptor agonist for different doses compared groups; only 10-mg dose lower than placebo. (pooled separately), did not increase types. Despite greater increments serum calcitonin 10- 15-mg reported cases papillary thyroid carcinoma. ConclusionTirzepatide use over weeks risk.

Language: Английский

Citations

3
Reasons for discontinuing tirzepatide in randomized controlled trials: A systematic review and meta-analysis DOI

A. B. M. Kamrul‐Hasan,

Joseph M Pappachan, Deep Dutta

et al.

World Journal of Diabetes, Journal Year: 2025, Volume and Issue: 16(4)

Published: Feb. 28, 2025

Despite therapeutic benefits, discontinuation of tirzepatide is common in randomized controlled trials (RCTs) due to adverse events (AEs) and other causes. No previous systematic reviews have explored the reasons for discontinuing RCTs. To explore permanent vs controls [placebo, insulin, glucagon-like peptide-1 receptor agonists (GLP-1Ras)] Relevant RCTs were systematically searched using related terms through multiple databases such as MEDLINE (via PubMed), Scopus, Cochrane Central Register, ClinicalTrials.gov from their inception until June 20, 2024. RevMan web was used conduct meta-analysis random-effects models. Outcomes presented risk ratios (RR) with 95% confidence intervals (CI). Seventeen (n = 14645), mostly having low risks bias, analyzed. Compared placebo, study drug substantially lower 10 mg (RR: 0.69, 95%CI: 0.51-0.93, P 0.02) similar 5 0.74, 0.47-1.17, 0.20) 15 0.94, 0.68-1.31, 0.71). Tirzepatide had identical when compared insulin at 0.96, 0.75-1.24, 0.77) 1.19, 0.77-1.82, 0.44) doses, whereas higher than 1.31, 1.03-1.67, 0.03). GLP-1RA, 0.98, 0.70-1.37, 0.90) but 1.40, 1.03-1.90, 0.03) 1.70, 1.27-2.27, 0.0004). Tirzepatide, all AE-related insulin; only greater doses placebo or GLP-1RA. Discontinuation withdrawal by subjects insulin. (all doses) conferred a causes not specifically mentioned. The group arm. Many factors AEs led included

Language: Английский

Citations

0
Case Report: Amelioration of severe metabolic dysfunction-associated steatohepatitis after switching from conventional GLP-1RAs to tirzepatide DOI Creative Commons
Yuki Oe, Takashi Omori,

Eriko Aimono

et al.

Frontiers in Endocrinology, Journal Year: 2025, Volume and Issue: 16

Published: May 26, 2025

Metabolic dysfunction-associated steatohepatitis (MASH) has cardiometabolic risk factors, such as obesity and type 2 diabetes, been reported to have a potentially higher of mortality than conventional steatotic liver diseases. Liver fibrosis develops can progress cirrhosis hepatocellular carcinoma. Although some antidiabetic agents ameliorate the condition, no specific medical treatment developed date. Tirzepatide is dual glucose-dependent insulinotropic polypeptide glucagon-like peptide-1 (GLP-1) receptor agonist (GLP-1RA) that shown efficacy against MASH in clinical trials. However, these trials were limited those with mild-to-moderate their history was often unclear. Here, we report case 50-year-old man 16-year diabetes. He demonstrated poor control his diabetes elevated enzymes. A biopsy performed he diagnosed steatohepatitis. Liraglutide administered for 3 years but function glycemic deteriorated gradually second 2023. The histological examination found liraglutide switched tirzepatide. Over 6 months administration tirzepatide, patient’s glycated hemoglobin enzyme levels improved. third performed, which showed marked improvement histology, amelioration fibrosis. diagnosis disease made. previous studies had an prognosis patients following GLP-1RA treatment, effective medications severe or who are refractory GLP-1RAs not identified We whose condition ameliorated by switching from

Language: Английский

Citations

0
Impact of Visceral and Hepatic Fat on Cardiometabolic Health DOI Creative Commons
Tasveer Khawaja,

Matthew Nied,

Abigail Wilgor

et al.

Current Cardiology Reports, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 5, 2024

Language: Английский

Citations

2
Associations between visceral and liver fat and cardiac structure and function: a UK Biobank study DOI Creative Commons

Zhi Lv,

Yangzhi Fu,

Yao Ma

et al.

The Journal of Clinical Endocrinology & Metabolism, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 14, 2024

Abstract Context Different fat depots have different associations connected to cardiovascular health. Objective We assessed the of abdominal magnetic resonance–quantified visceral adipose tissue (VAT) and liver (proton density fraction, PDFF) with cardiac resonance (CMR)-measured structure function, we considered potential mechanisms. Methods Our study encompassed 10 920 participants from UK Biobank. utilized multiple linear regression mediation analyses estimate connections between VAT or PDFF CMR metrics. Results Elevated exhibited adverse left ventricular (LV) (increased wall thickness, concentric LV remodeling), impaired function (lower global functional index, absolute value longitudinal strain), diminished atrial volumes stroke volume (all P values were significant). Upon stratifying based on combinations, all groups, except low VAT-low group, linked unfavorable remodeling The high VAT-high group displayed most pronounced alterations. Multiple employed investigate mediating roles systolic blood pressure (SBP), diabetes, dyslipidemia, biomarkers (lipidemia, transaminases) in adipose-CMR relationship. findings suggested that was related SBP, lipid profile, glucose. Several pathways identified, primarily through SBP triglyceride-glucose which only partially explained Conclusion established independent unhealthy function. Furthermore, it identifies insulin resistance as important factors.

Language: Английский

Citations

1
Pancreatic Safety of Tirzepatide and Its Effects on Islet Cell Function: A Systematic Review and Meta‐Analysis DOI Creative Commons
A B Kamrul-Hasan, Sunetra Mondal, Deep Dutta

et al.

Obesity Science & Practice, Journal Year: 2024, Volume and Issue: 10(6)

Published: Dec. 1, 2024

ABSTRACT Background Endogenous glucagon‐like peptide‐1 (GLP‐1) and glucose‐dependent insulinotropic polypeptide (GIP) regulate islet cell function. GLP‐1 receptor agonists (GLP‐1RAs) have been associated with an elevated risk of acute pancreatitis. Data on the pancreatic safety tirzepatide (a dual GIP agonist) its effects function in randomized controlled trials (RCTs) are scarce. Moreover, no meta‐analysis has comprehensively examined such tirzepatide. Methods Electronic databases were searched for RCTs as intervention a placebo or active comparator control. The primary outcome was adjudication‐confirmed pancreatitis; secondary outcomes percent changes from baseline serum amylase, lipase, insulin, C‐peptide, glucagon, homeostasis model assessment insulin resistance (HOMA2‐IR). Results Seventeen 18 published reports involving 14,645 subjects analyzed. Over follow‐up duration 12–72 weeks, had identical risks pancreatitis to (tirzepatide 5 mg: RR 2.04, 95% CI [0.27–15.69], p = 0.49; 10 0.63, [0.08–5.12], 0.67; 15 1.26, [0.36–4.98], 0.72). Tirzepatide also comparable GLP‐1RAs. However, (at all doses) caused greater increases amylase lipase than insulin. Individuals mg GLP‐1RAs similar having increased levels. reductions fasting placebo. All doses glucagon Compared GLP‐1RAs, HOMA2‐IR Conclusion provides evidence regarding establishes positive effect functions resistance.

Language: Английский

Citations

1
Tirzepatide, a dual receptor agonist of glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1, enhances β‐cell survival and maintenance markers in obese diabetic ovariectomized mice DOI
Pedro H. Reis‐Barbosa, Márcia Barbosa Águila, Carlos Alberto Mandarim‐de‐Lacerda

et al.

Diabetes Obesity and Metabolism, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 22, 2024

Language: Английский

Citations

0
Renal effects and safety of tirzepatide in subjects with and without diabetes: A systematic review and meta-analysis DOI
A B Kamrul-Hasan, Shinjan Patra, Deep Dutta

et al.

World Journal of Diabetes, Journal Year: 2024, Volume and Issue: 16(2)

Published: Dec. 30, 2024

Type 2 diabetes (T2D), as well obesity, are risk factors for chronic kidney disease (CKD) and end-stage renal disease. The impacts of glucose-lowering weight-lowering drugs their potential benefits in preventing CKD often guide clinicians choosing them appropriately. Only limited data based on randomized controlled trials (RCTs) is currently available the effects safety profile tirzepatide. To explore tirzepatide vs controls. RCTs involving patients receiving any indication intervention arm placebo or active comparator control were searched through multiple electronic databases. co-primary outcomes percent change from baseline (CFB) urine albumin-to-creatinine ratio (UACR) absolute CFB estimated glomerular filtration rate (eGFR; mL/min/1.73 m2); secondary outcome was tirzepatide's profile. RevMan web used to conduct meta-analysis using random-effects models. Outcomes presented mean differences (MD) ratios with 95% confidence intervals. Fifteen (n = 14471) mostly low bias (RoB) included. Over 26-72 weeks, 10 mg [MD -26.95% (-40.13, -13.76), P < 0.0001] 15 -18.03% (-28.58, -7.47), 0.0008] superior reductions UACR. Tirzepatide, at all doses, outperformed insulin Compared placebo, UACR reduction greater subjects T2D than those obesity but without (MD -33.25% -7.93%; 0.001). eGFR doses comparable [5 mg: MD 0.36 (-1.41, 2.14); 1.17 (-0.22, 2.56); 1.42 (-0.04, 2.88)]; > 0.05 all] insulin. Tirzepatide (pooled separate doses) did not increase risks adverse events, urinary tract infection, nephrolithiasis, acute injury, cancer compared insulin, glucagon-like peptide-1 receptor agonists. Short-term RoB suggests that positively detrimental T2D, a reassuring Larger warranted prove longer-term tirzepatide, which might also prevent decline worsening CKD.

Language: Английский

Citations

0